August 28, 2020Open Access

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Milton Packer

Stefan D. Anker

Javed Butler

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

University of Toronto

Massachusetts General Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider